Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without ...

Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

Scancell Holdings PLC SCLP Stock XLON Rating as of Nov 29, 2024 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating Performance Dividends ...

Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) shot up 7% during trading on Wednesday following insider buying activity. The company traded as high as GBX 10.43 ($0.14) and last ...